000			01958 a2200505 4500
005			20250515175429.0
264		0	_c20091104
008			200911s 0 0 eng d
022			_a1437-160X
024	7		_a10.1007/s00296-009-0973-9 _2doi
040			_aNLM _beng _cNLM
100	1		_aGoh, L
245	0	0	_aA systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. _h[electronic resource]
260			_bRheumatology international _cAug 2009
300			_a1123-35 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAdalimumab
650	0	4	_aAnti-Inflammatory Agents _xtherapeutic use
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aDiphosphonates _xtherapeutic use
650	0	4	_aEtanercept
650	0	4	_aHumans
650	0	4	_aImmunoglobulin G _xtherapeutic use
650	0	4	_aImmunosuppressive Agents _xtherapeutic use
650	0	4	_aInfliximab
650	0	4	_aInterleukin 1 Receptor Antagonist Protein _xtherapeutic use
650	0	4	_aIsoxazoles _xtherapeutic use
650	0	4	_aLeflunomide
650	0	4	_aMeta-Analysis as Topic
650	0	4	_aMethotrexate _xtherapeutic use
650	0	4	_aMulticenter Studies as Topic
650	0	4	_aPamidronate
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aReceptors, Interleukin-1 _xantagonists & inhibitors
650	0	4	_aReceptors, Tumor Necrosis Factor _xtherapeutic use
650	0	4	_aSpondylitis, Ankylosing _xdrug therapy
650	0	4	_aSteroids _xtherapeutic use
650	0	4	_aSulfasalazine _xtherapeutic use
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
700	1		_aSamanta, A
773	0		_tRheumatology international _gvol. 29 _gno. 10 _gp. 1123-35
856	4	0	_uhttps://doi.org/10.1007/s00296-009-0973-9 _zAvailable from publisher's website
999			_c18979375 _d18979375